Literature DB >> 16774007

Current status of hemodialysis treatment in Beijing, China.

Li Zuo1, Mei Wang.   

Abstract

INTRODUCTION: Since the Beijing Hemodialysis Quality Control and Improvement Center was established in 2002, some registration work on hemodialysis (HD) has been done. We report here the current status of HD in Beijing, the capital of China.
METHODS: Data collection forms were distributed to all HD centers in Beijing, and data from 2003 and 2004 were collected for analysis of incidence, prevalence, causes, and mortality of end-stage renal disease treated by HD.
RESULTS: Beijng has 122 HD centers. The point prevalence was 235.9 per million population at the end of 2003, and this number increased to 268.9 per million population by the end of 2004. The most common cause of ESRD was chronic glomerulonephritis, followed by diabetes and hypertension. The percentage of patients who met the target of Kidney Disease Outcome Quality Initiative guidelines for Kt/V, hemoglobin, and calcium-phosphate product were relatively low.
CONCLUSIONS: This report describes the current status of HD treatment in Beijing. The result shows that the prevalence and incidence of HD are increasing. Thus, for better prevention of ESRD, efforts should be made to clarify the reason for the increase. Also, the quality of health care provided needs to be improved for better quality of life for patients on HD.

Entities:  

Mesh:

Year:  2006        PMID: 16774007

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  8 in total

1.  The Spectrum of Biopsy-Proven Glomerular Diseases among Children in China: A National, Cross-Sectional Survey.

Authors:  Sheng Nie; Wenjuan He; Ting Huang; Diankun Liu; Guobao Wang; Jian Geng; Nan Chen; Gang Xu; Ping Zhang; Yang Luo; Jing Nie; Xin Xu; Fan Fan Hou
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-18       Impact factor: 8.237

2.  Clinical characteristics and outcomes of rural patients with ESRD in Guangxi, China: one dialysis center experience.

Authors:  Wenxin Zhang; Zhifeng Gong; Xiaomei Peng; Sheng Tang; Ming Bi; Wentan Huang
Journal:  Int Urol Nephrol       Date:  2009-07-14       Impact factor: 2.370

3.  Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study.

Authors:  Brian Bieber; Jiaqi Qian; Shuchi Anand; Yucheng Yan; Nan Chen; Mia Wang; Mei Wang; Li Zuo; Fan Fan Hou; Ronald L Pisoni; Bruce M Robinson; Sylvia P B Ramirez
Journal:  Nephrol Dial Transplant       Date:  2013-12-08       Impact factor: 5.992

4.  Association of CKD-MBD Markers with All-Cause Mortality in Prevalent Hemodialysis Patients: A Cohort Study in Beijing.

Authors:  Duo Li; Ling Zhang; Li Zuo; Cheng Gang Jin; Wen Ge Li; Jin-Bor Chen
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

5.  Association between the risk of death and serum calcium, phosphate, and intact parathyroid hormone levels in older patients undergoing maintenance hemodialysis: a cohort study in Beijing.

Authors:  Dishan Li; Wenhu Liu; Hongdong Huang; Wang Guo; Zongli Diao; Xinpan Chen; Weiwei Wangs
Journal:  Ther Adv Endocrinol Metab       Date:  2021-06-25       Impact factor: 3.565

6.  Impact of individual and environmental socioeconomic status on peritoneal dialysis outcomes: a retrospective multicenter cohort study.

Authors:  Rong Xu; Qing-Feng Han; Tong-Ying Zhu; Ye-Ping Ren; Jiang-Hua Chen; Hui-Ping Zhao; Meng-Hua Chen; Jie Dong; Yue Wang; Chuan-Ming Hao; Rui Zhang; Xiao-Hui Zhang; Mei Wang; Na Tian; Hai-Yan Wang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  Current status of maintenance hemodialysis in Beijing, China.

Authors:  Li Zuo; Mei Wang
Journal:  Kidney Int Suppl (2011)       Date:  2013-05

8.  Epidemiological Study of RRT-Treated ESRD in Nanjing - A Ten-Year Experience in Nearly Three Million Insurance Covered Population.

Authors:  Yu-Chen Han; Han-Ming Huang; Ling Sun; Chao-Ming Tan; Min Gao; Hong Liu; Ri-Ning Tang; Yan-Li Wang; Bei Wang; Kun-Ling Ma; Bi-Cheng Liu
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.